D.E. Shaw & Co
PASG icon

D.E. Shaw & Co’s Passage Bio PASG Stock Holding History

D.E. Shaw & Co’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-501
Closed -$6.6K – 4527
2023
Q3 		$6.6K Sell
501
-6,214
-93% -$102K ﹤0.01% 4110
2023
Q2 		$126K Sell
6,715
-7,002
-51% -$139K ﹤0.01% 3807
2023
Q1 		$263K Sell
13,717
-4,421
-24% -$120K ﹤0.01% 3800
2022
Q4 		$501K Sell
18,138
-819
-4% -$20.7K ﹤0.01% 3851
2022
Q3 		$474K Buy
18,957
+839
+5% +$33.1K ﹤0.01% 4067
2022
Q2 		$855K Buy
18,118
+3,081
+20% +$144K ﹤0.01% 3738
2022
Q1 		$932K Buy
15,037
+8,242
+121% +$679K ﹤0.01% 3973
2021
Q4 		$863K Buy
+6,795
New +$1.11M ﹤0.01% 4049

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's PASG Position: Q4 2023 in Review

D.E. Shaw & Co sold out of Passage Bio (PASG) in Q4 2023, closing a stake of 501 shares — an estimated $6.6K sold.

D.E. Shaw & Co first reported a position in PASG in Q4 2021 and held it in 8 quarters. The position peaked at $932K in Q1 2022. 50 funds tracked by Wall St. Rank hold PASG as of Q4 2023.

  • D.E. Shaw & Co reported no remaining Passage Bio position as of Q4 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 501 Passage Bio shares in Q4 2023, an estimated $6.6K.
  • D.E. Shaw & Co first reported a position in Passage Bio in Q4 2021 and held it in 8 quarters.
  • D.E. Shaw & Co's Passage Bio position peaked at $932K in Q1 2022.
  • 50 funds tracked by Wall St. Rank held Passage Bio as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.